Amgen Inc. is a prominent biotech company with a market cap of $158.6 billion, focusing on developing human therapeutics for serious illnesses. Analysts expect a 10.2% decrease in profit for Q3 2025 compared to the prior year. Fiscal 2025 predictions forecast a 6.4% increase in EPS from fiscal 2024.

Over the past year, AMGN stock has declined 8.4%, trailing behind the S&P 500 and Health Care Select Sector SPDR Fund. Following a $650 million investment in expanding its manufacturing facility, shares surged 6.4%. Analysts give AMGN a “Moderate Buy” rating with a $315.26 price target, indicating a 6.7% potential upside.

Read more at Yahoo Finance: Here’s What to Expect From Amgen’s Next Earnings Report